| Story
Posted: November 08, 2007
Canola Council of Canada builds science behind
healthy canola oil
The Canola Council of Canada has collaborated
with canola industry partners to establish a major fund to support
innovative research linking canola oil to improving the health
of all Canadians.
(Media Release from the Canola Council of Canada)
The Canola Product Research Fund is backed by
the Canola Council, the three prairie canola grower associations,
Bayer CropScience, Dow AgroSciences Canada, Monsanto Canada and
Pioneer Hi-Bred.
Council president JoAnne Buth says the new Fund
"will focus on supporting leading edge research on the role
of canola oil in reducing the risk of major health conditions
such as diabetes and cardiovascular disease".
"We look on the Canola Product Research
Fund as essential seed money to build the science behind what
we already know about the healthy properties of canola oil,"
Buth says. "Over the next few months, we would hope to see
even more financial support from both inside and outside the canola
industry."
Buth explains that the funds committed so far
will be allocated to three major projects involving clinical trials
on human nutrition and canola oil.
Two studies will begin this fall, focusing on
1) the efficacy of canola oil in the management of high cholesterol
and other heart disease risk factors and 2) the impact of canola
oil on insulin resistance in adults at risk of type 2 diabetes.
A third study approved for funding will examine the effect of
canola oil on blood sugar control and heart disease risk factors
in adults with type 2 diabetes.
As well as substantiating and reinforcing the
heart-healthy position of canola oil, Buth expects the project
results "may also provide new research data in the field
of diabetes that can be used to further market canola oil".
The Canola Council is also partnering with Syngenta
and with the Natural Sciences and Engineering Research Council
of Canada (NSERC) to fund a research initiative at the University
of Manitoba designed to investigate minor components in canola
oil and meal with enhanced nutraceutical properties.
Canola Product Research Fund Background
Information
In the first study, Dr. Peter Jones and colleagues at the
Richardson Centre for Functional Foods & Nutraceuticals at
the University of Manitoba, will conduct a trial with people with
borderline high cholesterol levels. A diet containing canola oil
(70% of total fat) will be compared to a control diet comprised
of largely saturated and omega-6 fatty acids.
The results are expected to demonstrate the
positive effects of alpha-linolenic acid (ALA), the omega-3 fatty
acid found in canola oil and oleic acid (a monounsaturated fatty
acid found at very high levels in canola oil) on several indicators
of inflammation and blood vessel cell dysfunction characteristic
of coronary heart disease.
The second study will look at the potential
beneficial effects of a diet high in monounsaturated and omega-3
fatty acids from canola oil in overweight women at risk for type
2 diabetes.
Dr. Sheila Innis of the Faculty of Medicine
Pediatrics, University of British Columbia, and research associates
will reduce saturated and omega-6 fatty acid intake in the subjects
and increase their consumption of monounsaturated and omega-3
fatty acids through a diet high in canola oil.
The study is expected to show that monounsaturated
and omega-3 fatty acids have a positive health impact, especially
on measures of inflammation believed to be a determinant for onset
and progression in both diabetes and cardiovascular disease (CVD).
The third study approved for funding
will be undertaken by Dr. David Jenkins of the Faculty of Medicine,
University of Toronto once matching research funds are found.
Jenkins will study the impact of canola oil on blood sugar control
and heart disease risk factors in patients with type 2 diabetes.
The study is expected to show that subjects
who consume canola oil will have better blood glucose control,
blood lipid profiles, and reduced indicators of inflammation associated
with heart disease and diabetes compared to subjects consuming
diets low in ALA.
< Back to main
Latest News & Events page |